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Resistin Mediates sex-Dependent 
Effects of Perivascular Adipose 
Tissue on Vascular Function in the 
Shrsp
Heather Yvonne Small, Sarah McNeilly, Sheon Mary, Adam Marcus Sheikh & Christian Delles  
Premenopausal women are relatively protected from developing hypertension compared to men. 
Perivascular adipose tissue (PVAT) has been shown to mediate vasoactive effects; however, a sex-
dependent difference in PVAT function in the setting of hypertension has not yet been explored. We 
investigated the effect of PVAT on resistance vessel biology in male and female 16 week old stroke 
prone spontaneously hypertensive rats (SHRSP). This preclinical model of hypertension exhibits a sex-
dependent difference in the development of hypertension similar to humans. Wire myography was used 
to assess vascular function in third-order mesenteric arteries. KATP channel-mediated vasorelaxation 
by cromakalim was significantly impaired in vessels from SHRSP males + PVAT relative to females 
(maximum relaxation: male + PVAT 46.9 ± 3.9% vs. female + PVAT 97.3 ± 2.7%). A cross-over study 
assessing the function of male PVAT on female vessels confirmed the reduced vasorelaxation response 
to cromakalim associated with male PVAT (maximum relaxation: female + PVATfemale 90.6 ± 1.4% 
vs. female + PVATmale 65.8 ± 3.5%). In order to explore the sex-dependent differences in PVAT at 
a molecular level, an adipokine array and subsequent western blot validation identified resistin 
expression to be increased approximately 2-fold in PVAT from male SHRSP vessels. Further wire 
myography experiments showed that pre-incubation with resistin (40 ng/ml) significantly impaired 
the ability of female + PVAT vessels to relax in response to cromakalim (maximum relaxation: 
female + PVAT 97.3 ± 0.9% vs. female + PVAT + resistin[40ng/ml] 36.8 ± 2.3%). These findings indicate 
a novel role for resistin in mediating sex-dependent vascular function in hypertension through a KATP 
channel-mediated mechanism.
Worldwide, hypertension affects more than 40% of people over 25 years of age and is the single biggest risk factor 
for the development of cardiovascular disease1. Overall, there is no difference in the prevalence of hypertension 
between adult (≥20 years old) men and women. However, it is well-established that men develop hypertension 
at an earlier age than women2. One of the candidates proposed to explain this sex-dependent difference is the 
presence of estrogen. Estrogen has been shown to be protective against the development of hypertension through 
acting as a vasodilator, inhibiting the sympathetic nervous system, regulating the renin-angiotensin sytem and by 
reducing renal damage3–5. In spite of this knowledge, the effect of treatments such as hormone replacement ther-
apy have been inconclusive with regard to a beneficial effect of estrogen on the development of cardiovascular dis-
ease6–8. Research is required to fully delineate the pathophysiological mechanisms underlying the sex-dependent 
difference in the development of hypertension. Specifically, the role of perivascular adipose tissue (PVAT), an 
important modulator of vascular function, has yet to be investigated.
PVAT is the fat reserve surrounding blood vessels and consists of adipocytes, immune cells, fibroblasts and 
endothelial cells9,10. Depending on its location, it has the characteristics of either brown or white adipose tis-
sue. The former is thermogenic and primarily involved in energy expenditure, whereas the latter is believed 
to serve as energy storage. The thoracic aorta is surrounded by brown adipose tissue, whereas the abdominal 
aorta and mesenteric arteries are surrounded by white adipose tissue9. In addition to acting as structural sup-
port and protection for vessels, PVAT also has direct effects on the vasculature11. This phenomenon was first 
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discovered in 1991 by Soltis and Cassis who showed that PVAT asserted anti-contractile effects on vessels through 
so-called ‘adventitium derived relaxing factors’ (ADRF)10. These ADRFs affect vasorelaxation by acting through 
the opening of potassium channels leading to calcium influx and hyperpolarisation. These mechanisms can be 
both endothelium-dependent and independent. Several ADRF candidates have been proposed experimentally, 
such as, adiponectin, angiotensin 1–7, hydrogen sulphide and prostacyclins12. With respect to hypertension, stud-
ies in a number of preclinical models have concluded that a reduction of PVAT mediated anti-contractile effect 
contributes to an increase in blood pressure13–16. Underlying causes have been attributed to the increased release 
of inflammatory factors stimulating the production of contractile agents such as angiotensin II and superoxide 
from the PVAT. Further, a reduction in ADRF or potassium channels in the PVAT or vascular smooth muscles 
cells may also contribute17.
Here, we hypothesize that there is an alteration in PVAT function between males and females, which contrib-
utes to the sex-dependent difference observed in the development of hypertension. We utilized the stroke-prone 
spontaneously hypertensive rat (SHRSP) to investigate the differences between male and female PVAT. The 
SHRSP is a well-established model of cardiovascular disease sharing many of the pathologies seen in humans; 
including the sex difference observed in hypertension18. This difference is observed from 12 weeks of age, but 
more pronounced at 16 weeks, when the systolic blood pressure of male SHRSP is approximately 30 mmHg 
higher than female SHRSP19. This study used age-matched 16 week old male and female SHRSP to explore 
sex-dependent differences in PVAT function in hypertension using ex vivo and molecular-based studies.
Methods
Animals. Animals (strain: SHRSP and WKY) were housed under controlled lighting (0700–1900 hours) and 
temperature (21 ± 3 °C) and received a normal diet (rat and mouse no.1 maintenance diet; Special Diet Services, 
Grangemouth, United Kingdom) provided ad libitum. All animal procedures were approved by the Home Office 
according to the regulations on experiments with animals in the United Kingdom (Project License Number 
60/4286). In this study, all animals were age matched at 16 weeks of age (±4 days). Experiments were carried out 
according to the guidelines of ARRIVE and Directive 2010/63/EU of the European Parliament on the protection 
of animals used for scientific purposes. The number of animals used for a given experiment is indicated in the 
associated figure legend.
PVAT weight measurement. Prior to the wire-myography experiments, PVAT of male and female WKY 
and SHRSP was dissected from 3 vessels per animal and weighed to assess the average amount of PVAT per vessel.
Wire myography. Rings for wire myography were consistently prepared from third-order mesenteric arter-
ies (average diameter 250 µm) harvested in physiological salt solution (PSS) (0.25 M NaCl, 0.001 M KCl, 2 mM 
MgSO4, 50 mM NaHCO3, 2 mM KH2PO4, 1 mM glucose, 2.5 mM CaCl2) from 16 week old male and female 
WKY and SHRSP. Mesenteric artery rings (1.8–2.0 mm in length) with or without (+/−) PVAT were mounted 
on two stainless steel wires on a four channel small vessel myograph (AD Instruments, Oxford, UK) in PSS. 
Vessels were normalized and subject to a wake-up procedure using high potassium PSS1. To establish the ves-
sel’s contractile response, noradrenaline (Sigma-Aldrich, Dorset, UK) was added at the following increasing 
concentrations: 1 × 10−9, 1 × 10−8, 1 × 10−7, 1 × 10−6, 3 × 10−6, 1 × 10−5 and 3 × 10−5 M. To determine the ves-
sel’s endothelium-dependent relaxation response, vessels were pre-constricted with 1 × 10−5 M noradrenaline 
followed by the addition of carbachol (Sigma-Aldrich, Dorset, UK) at the following increasing concentrations: 
1 × 10−9, 1 × 10−8, 1 × 10−7, 1 × 10−6 and 1 × 10−5 M. To assess KATP channel mediated relaxation, vessels were 
pre-constricted with 1 × 10−5 M noradrenaline followed by the addition of cromakalim (Sigma-Aldrich, Dorset, 
UK) at following concentrations: 1 × 10−9, 1 × 10−8, 1 × 10−7, 1 × 10−6, 1 × 10−5 and 3 × 10−5 M. At the low con-
centration used, cromakalim could be dissolved in PSS. SNP was used as a positive control for vasorelaxation.
Resistin pre-incubation. For wire myography experiments carried out to assess the effect of resistin, vessels 
were mounted on the small vessel wire myograph followed by incubation with 40 ng/ml recombinant rat resistin 
(Sigma-Aldrich, Dorset, UK) for 4 hours at 37 °C. Following incubation, vessels were subject to dose-response 
curves as described in “Wire myography”.
Cross-over study. To determine the sex specific effects of male and female PVAT, a cross-over study was 
devised. For this, PVAT was dissected from female vessels, weighed (average weight approximately 10 µg) and 
attached to the heads of the small vessel myograph with a stainless steel wire (Fig. S1). PVAT was used on the 
same day as it was harvested in these studies. This ensured close proximity of the vessel to the PVAT. Attaching 
the PVAT best replicates the physiologically relevant setting of endogenous PVAT. Prior to the experiment, the 
set up was compared to vessels with intact PVAT to exclude potential interference of the additional wire (Fig. S4). 
The same procedure was carried out using male PVAT on female vessels. Vessels were subject to dose-response 
curves as described in “Wire myography”.
Histopathology. Mesenteric vessels with intact PVAT were harvested from male and female WKY and 
SHRSP and fixed for 24 hours in 10% formalin. Paraffin sections of 5 µm were used for staining. Immediately prior 
to staining, slides were deparaffinised and rehydrated through an ethanol gradient into distilled H2O. Sections 
were stained with haematoxylin and eosin using standard protocol. This was followed by 1 minute under running 
tap water and dehydration through an ethanol gradient and mounted using DPX (Sigma-Aldrich, Dorset, UK). 
Sections were viewed using light microscopy taken at 20x objective. Adipocyte density and size was quantified 
using Image J (National Institutes of Health, Bethesda, USA). Sections were analysed by an operator who was 
blinded to the identity of the slides.
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Adipokine array. The rat Proteome Profiler™ array (R&D Systems, Abingdon, UK) was carried out according 
to manufacturer’s instructions. In brief, snap frozen tissue was homogenized in PBS with protease inhibitors (Roche 
Laboratories, Welwyn Garden City, UK) and frozen in 1% Triton-X at −80 °C before use. Total protein concentration 
was then assessed using Bradford reagent (Sigma-Aldrich, Dorset, UK) where 250 µg was used for the adipokine array. 
Biotinylated antibodies were then mixed with the sample and incubated with the membrane overnight at 4 °C. The next 
day, the membrane was washed and incubated with Strepdavidin-HRP. After further washes, Chemi Reagent mix was 
distributed evenly on the membranes and visualised using the Licor Ci-DiGit (Licor, Cambridge, UK).
Western blot. Snap frozen tissue was homogenized in PBS with protease inhibitors (Roche Laboratories, 
Welwyn Garden City, UK) and frozen in 1% Triton-X at −80 °C before use. Protein concentration was measured 
using the Pierce™ BCA Protein Assay Kit (Thermo Fisher, Renfrew, UK). A total of 30 µg was loaded into each 
well. The membrane was blocked with 5% fat-free milk before incubation with the primary antibody for resistin 
(#ab93069, Abcam, Cambridge, UK). Membranes were incubated with an anti-chicken HRP-conjugated second-
ary antibody (#ab191865, Abcam, Cambridge, UK). Proteins were detected using Amersham enhanced chemi-
luminescence (ECL) western blotting detection reagents (GE Life Sciences, Buckinghamshire) in a 1:1 ratio and 
visualised with the Licor Ci-DiGit (Licor, Cambridge, UK).
Data analysis. Statistical analysis was performed using performed using GraphPad Prism version 4.0 for 
Windows (GraphPad Software, La Jolla California, USA). Error bars in all graphs are indicative of standard error 
of the mean. A Student’s t-test was employed where 2 groups were compared and one way ANOVA followed by 
Figure 1. Male and female SHRSP exhibit different third-order mesenteric artery function in the absence and 
presence of PVAT. Wire myography was used to assess mesenteric artery function in age-matched (16 weeks 
old) male (n = 5) and female (n = 5) SHRSP. PVAT had an anti-contractile effect in both male and female (A). 
Vessels from male SHRSP - PVAT were more responsive to noradrenaline than vessels from female SHRSP - 
PVAT (A) (**p < 0.01; EC50 SHRSP male 1.84 ± 1.30 μM vs. SHRSP female 3.43 ± 0.41 μM followed by one way 
ANOVA and post-hoc Tukey test) (A). In addition, vessels from male SHRSP + PVAT were more responsive 
to noradrenaline than vessels from female SHRSP + PVAT (**p < 0.01; EC50 SHRSP male 6.13 ± 0.82 μM vs. 
SHRSP female 12.35 ± 1.27 μM followed by one way ANOVA and post-hoc Tukey test) (A). Vasorelaxation to 
cromakalim was impaired in vessels – PVAT from male SHRSP relative to vessels – PVAT from female SHRSP 
(*p < 0.05; area under the curve followed by one way ANOVA and post-hoc Tukey test) and in vessels + PVAT 
from male SHRSP relative to vessels + PVAT from female SHRSP (**p < 0.01; area under the curve followed by 
one way ANOVA and post-hoc Tukey test) (B). There was a trend for endothelium-dependent vasorelaxation 
to carbachol to be greater in vessels from female relative to male SHRSP; PVAT did not induce a significant 
difference in carbachol response in either strain (C). Vasorelaxation to SNP was not significantly different 
between strains; PVAT did not significantly alter the response to SNP in either strain (D).
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post-hoc Tukey test was used to compare >2 groups. The statistical test is given in the associated figure legend. A 
p-value of < 0.05 was considered to be statistically significant for all experiments.
Results
WKY and SHRSP exhibit altered mesenteric artery function in the presence of PVAT. Wire 
myography was used to assess mesenteric artery function in the presence or absence of PVAT in age-matched 
(16 week old) male WKY and SHRSP. PVAT had an anti-contractile effect in both WKY and SHRSP; however 
SHRSP + PVAT vessels were more responsive to noradrenaline than WKY (Fig. S1A,B). KATP channel-mediated 
vasorelaxation to cromakalim was not significantly different between WKY and SHRSP or in the presence or 
absence of PVAT (Fig. S1C). WKY and SHRSP mesenteric arteries +/− PVAT had a similar maximum vasorelax-
ation response to carbachol and sodium nitroprusside (SNP) (Fig. S1D,E). The presence or absence of PVAT did 
not significantly alter the response of the vessels to carbachol or cromakalim in either strain (Fig. S1D,E).
When normalised to bodyweight, SHRSP had a greater amount of PVAT surrounding their mesenteric arter-
ies than WKY (Fig. S2A). On histological examination, no strain-dependent difference was observed in adipocyte 
size or density (Fig. S2B,C).
Sex-dependent differences exist in PVAT function and structure in the SHRSP. Wire myogra-
phy was used to assess mesenteric artery function in the presence or absence of PVAT in age-matched (16 week 
old) male and female SHRSP. PVAT had an anti-contractile effect in both male and female SHRSP (Fig. 1A). 
Mesenteric arteries from male SHRSP had a greater contractile response to noradrenaline than vessels from 
females both in the presence or absence of PVAT (Fig. 1A). Vasorelaxation to cromakalim was significantly 
impaired in vessels from male SHRSP relative to female SHRSP (Fig. 1B). Vessels from female SHRSP +/− PVAT 
exhibited a trend to be more responsive to carbachol than vessels from males; however this was not statistically 
significant (Fig. 1C). Vasorelaxation to SNP was not significantly different between strains or in the presence 
or absence of PVAT (Fig. 1D). The equivalent experiment in WKY did not show a sex-dependent difference in 
vascular function (Fig. S3).
There was no difference in the weight of PVAT which surrounded the mesenteric arteries between male and 
female SHRSP (Fig. 2A). Histological analysis using haematoxylin and eosin stain revealed that male SHRSP 
adipocytes were larger in size and reduced in density relative to females (quantification: Fig. 2B,C; representative 
images Fig. 2D,E).
PVAT from SHRSP males has a lesser anti-contractile effect and impairs cromakalim-mediated 
vasorelaxation in female vessels. PVAT taken from male SHRSP mesenteric arteries was “crossed-over” 
to female vessels - PVAT and vice versa. As a control, the PVAT for the same sex vessel was removed and 
replaced in an identical way. This cross-over method was compared to the endogenous PVAT response which 
showed it did not alter the response of the vessel (Fig. S4). Cross-over of female PVAT on to a female vessel 
elicited a significant anti-contractile response, however the reciprocal male PVAT cross-over did not (Fig. 3A). 
Furthermore, cross-over of male PVAT on to a female vessel impaired the vasorelaxation response to cromakalim 
Figure 2. SHRSP males have larger adipocytes in the PVAT surrounding the third-order mesenteric arteries 
relative to females. PVAT surrounding the mesenteric artery was weighed (3 vessels/animal) in age matched (16 
weeks old) male (n = 10) and female (n = 10) SHRSP. When normalised to body weight there was no significant 
difference in the amount of PVAT surrounding the mesenteric arteries between male and female SHRSP (A). 
On histological analysis, adipocytes size was greater and adipocyte density lesser in the male SHRSP relative to 
the female SHRSP (B,C) (**p < 0.01; Student’s t-test). Representative histology sections of the PVAT adipocytes 
are shown in (D,E). Scale bar represents 50 μm.
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(Fig. 3B). Both the cross-over of male and female PVAT on to male vessels had a significant anti-contractile 
effect (Fig. 3C). The cross-over of male or female PVAT on to male vessels did not have a significant effect on the 
cromakalim-mediated vasorelaxation; however there was a minor trend for female PVAT to improve vasorelax-
ation to cromakalim (Fig. 3D).
Resistin is differentially expressed in PVAT between male and female SHRSP. PVAT harvested 
from third-order mesenteric arteries of age-matched (16 week old) male and female SHRSP was subject to an 
adipokine array (full results in Fig. S5). The adipokine, resistin, was identified from this screen to show greater 
expression in PVAT from the male relative to the female SHRSP (Fig. 4A,B).
Resistin is vasoactive in the mesenteric arteries through impairing KATP channel mediated vas-
orelaxation. Third-order mesenteric arteries from age-matched (16 week old) male and female SHRSP were 
pre-incubated with a physiological concentration of recombinant rat resistin (40 ng/ml) at 37 °C for 4 hours before 
wire myography was used to assess vascular function. Pre-incubation with resistin did not significantly alter the 
contractile response of female vessels+/− PVAT (Fig. 5A), however, the vasorelaxation response to cromakalim 
was significantly impaired in both female vessels +/− PVAT (Fig. 5B). In male vessels, resistin pre-incubation did 
not alter the contractile response to noradrenaline or vasorelaxation response to carbachol (Fig. 5C,D).
Discussion
Altered PVAT function contributes to the sex-dependent differences in resistance vessel function in the 
SHRSP through exhibiting a reduced anti-contractile effect in males compared to females. Further, KATP 
channel-mediated relaxation was reduced in male third-order mesenteric arteries. Resistin was identified to be 
up-regulated in PVAT from male vessels compared to females. Incubating female vessels with male PVAT or 
resistin abrogated KATP channel-mediated vasorelaxation. These findings establish a novel role for resistin in the 
sex-dependent effects of PVAT in the setting of hypertension through a KATP channel-mediated mechanism.
This is the first account in the SHRSP demonstrating reduced anti-contractile effects of PVAT in response 
to noradrenaline. In agreement with the data presented here, several other models of hypertension such as the 
Figure 3. Cross-over of PVAT from male SHRSP alters female third-order mesenteric artery function but not 
vice versa. Wire myography was used to assess mesenteric artery function in age-matched (16 weeks old) male 
(n = 10) and female (n = 10) SHRSP where PVAT from mesenteric arteries of SHRSP males was “crossed-over” 
on to mesenteric arteries (A,B) of female SHRSP and vice versa (C,D). Female PVAT had a significant anti-
contractile effect on female vessels (**p < 0.01; area under the curve followed by one way ANOVA and post-hoc 
Tukey test) however this was abolished when male PVAT was used (A). Cross-over of male PVAT on to female 
vessels impaired the vasorelaxation response to cromakalim (**p < 0.01; area under the curve followed by one 
way ANOVA and post-hoc Tukey test) (B). Cross-over of both male and female PVAT had a significant anti-
contractile effect on male vessels (*p < 0.05; area under the curve followed by one way ANOVA and post-hoc 
Tukey test). Cross-over of female PVAT on to the male vessel showed a trend to improve cromakalim-mediated 
vasorelaxation, however, this was not significant (D).
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spontaneously hypertensive rat (SHR) have been shown to exhibit dysfunctional PVAT13,15,20. Overall, the SHRSP 
have more adipose tissue than WKY and can also present with aspects of metabolic syndrome in contrast with 
the SHR which is purely a model of hypertension21. Increased adiposity has also been associated with reduced 
vascular function and increased cardiovascular disease which could be construed as a confounding factor in this 
study. A recent study by Bussey et al. showed that maintained weight loss was able to restore PVAT function; i.e. 
the reduction of PVAT led to the improvement of PVAT function22. Adipocytes in PVAT from female SHRSP 
vessels were significantly smaller than males. Differences in adipocyte size may contribute to a pathogenic func-
tion of PVAT since larger adipocytes are limited in further fat uptake and may lead to ‘overspill’ and ectopic fat 
storage causing formation of reactive oxygen species, endoplasmic reticulum stress and inflammation23; all of 
which have been associated with hypertension24–26. A greater number of smaller adipocytes on the other hand 
provides more storage for lipids27. In concordance with the findings, a study that examined abdominal fat of obese 
women showed an increase in adipose tissue mass was caused by hyperplasia rather than hypertrophy28. In this 
study, there was no difference between SHRSP and WKY with respect to endothelium-dependent vasorelaxa-
tion. This was unexpected given that endothelium-dependent vasorelaxation has been shown to be impaired in 
hypertension.
This study has demonstrated a clear sex-dependent difference between PVAT in male and female SHRSP, 
which contributes directly to vascular function. PVAT from resistance vessels of female SHRSP retain more 
anti-contractile ability than males. To dissect whether the apparent reduced anti-contractile effects in females was 
due to a less dysfunctional female PVAT or improved vessel function compared to males, the cross-over study was 
devised. These experiments showed that although female vessels have improved vessel function relative to males; 
female PVAT retains more beneficial effects compared to male PVAT. In contrast, male vessels when incubated 
with male or female PVAT displayed a similar anti-contractile effect. KATP channels are important contributors 
to the regulation of vascular tone29; mice lacking KATP channel subunits display increased hypercontractility and 
often die from sudden coronary artery spasms30. The KATP channel agonist cromakalim did not result in any dif-
ference in relaxation between the WKY and SHRSP males or between WKY males and females. When comparing 
male and female SHRSP, females were able to relax significantly more regarding both the EC50 and maximum 
Figure 4. Resistin is increased in PVAT from third-order mesenteric arteries of male relative to female SHRSP. 
PVAT (perivascular adipose tissue) protein extracts from mesenteric arteries of age-matched (16 week old) male 
SHRSP (n = 4) and female SHRSP (n = 4) were utilised for an adipokine array (A). Each visible spot on the array 
(A) is a technical duplicate from a panel of adipokines which was detected in the PVAT sample. Full results for 
the adipokine array are shown in Fig. S5. Resistin (identified by a black circle in (A)) was identified to be down-
regulated in PVAT from female SHRSP relative to male SHRSP (A) and quantified in (B) (ns; Student’s t-test).
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relaxation. This suggests a higher expression or preserved function of KATP channels in female vessels. This could 
also partially explain the decreased sensitivity of female vessels to noradrenaline stimulation. Corroborating our 
findings, other hypertensive models have shown a reduced expression of KATP channel subunits31. One limitation 
of this study is that it was not extended to include a specific KATP channel such as glibenclamide to provide addi-
tional evidence of a KATP mediated mechanism.
In agreement with our hypothesis that PVAT may play a significant role in the sex-dependent difference in 
the development of hypertension, a recent study showed that sex can also alter the immune response to exacer-
bate hypertension. Interestingly, an increased infiltrate of pro-inflammatory T-cells in PVAT was observed only 
in males in the hypertensive angiotensin II infusion mouse model32. The adipokine array identified resistin as 
a potential candidate for PVAT mediated sex specific effects in vascular function as this was elevated in males 
compared to females. Resistin, also known as adipose-tissue specific secretory factor (ADSF), is expressed at 
significant levels in adipocytes, macrophages and mononuclear leukocytes. Its name is derived from its ability to 
interfere with the action of insulin and is thought to be an important link between obesity and diabetes33,34. It has 
also been linked to other cardiovascular diseases such as atherosclerosis. In addition, it is thought to be involved 
in the pathology of autoimmune disease, such as rheumatic disease and inflammatory bowel syndrome35,36. There 
has been some debate concerning the translation of these findings discovered predominantly in preclinical mod-
els. However, recent work has shown that circulating resistin levels are elevated in both obese individuals with 
hypertension37, and in a seemingly healthy pre-hypertensive population38. Further, a recent study suggests resistin 
contribute to hypertension via TLR4 signalling. Resistin mediated TLR4 signalling can then lead to an NFκB 
mediated inflammatory response and upregulation of angiotensinogen exacerbating hypertension39. The main 
source of resistin in humans is macrophages rather than adipocytes, but it is well established that macrophages 
make up a significant portion of the cells found in PVAT40,41. Additionally, in inflamed PVAT, macrophages are at 
least in part responsible for PVAT dysfunction42.
The sex -dependent expression of resistin may be affected by the presence of estrogen. Estrogen has been 
shown to downregulate resistin expression both in vivo and in vitro43 and ovariectomized rats have increased 
levels of resistin in adipose tissue and serum44,45. Contrastingly, testosterone did not affect pituitary resistin levels 
in mice, suggesting it is the lack of estrogen and not the greater level of testosterone in males that affects resis-
tin expression46. However, this relationship has never been explored in the setting of vascular disease. In this 
Figure 5. Pre-incubation with resistin inhibits KATP channel mediated vasorelaxation to cromakalim in third-
order mesenteric arteries from female but not male SHRSP. Wire myography was used to assess mesenteric artery 
function in age-matched (16 weeks old) male (n = 5) and female (n = 5) SHRSP where vessels were pre-incubated 
prior to drug curves with 40 ng/ml resistin for 4 hours at 37 °C. Pre-incubation with resistin had no significant 
effect on the contractile response to noradrenaline of the female vessels +/− PVAT (A), however, vasorelaxation 
mediated by cromakalim was significantly impaired in female vessels both+/− PVAT (*p < 0.05, **p < 0.01; area 
under the curve followed by one way ANOVA and post-hoc Tukey test) (B). Pre-incubation with resistin had no 
significant effects on either the contractile response or the vasorelaxation response to cromakalim in male vessels 
(ns; area under the curve followed by one way ANOVA and post-hoc Tukey test) (C,D).
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study, male and female vessels were pre-incubated with resistin to investigate its direct effect on vascular func-
tion. The reported plasma concentration of resistin varies in humans from as low as 4 ng/ml47 to 39.9 ng/ml48. 
The relevant concentration of 40 ng/ml was chosen, owing to the relatively short incubation time of four hours 
needed to ensure viability of the vessels. Resistin did not have any effect on noradrenaline induced vasoconstric-
tion in males or females and did not alter KATP channel-mediated relaxation in males. However, in females KATP 
channel-mediated relaxation was significantly reduced. In line with this result, male PVAT also inhibited KATP 
channel mediated relaxation in female vessels in the ‘cross-over’ experiment. This suggests a direct PVAT medi-
ated effect via resistin, which results in reduced KATP channel mediated relaxation of mesenteric vessels.
The results presented in this study suggest a key role for PVAT in the sex difference in resistance vessel func-
tion in the SHRSP which may have a direct role in the development of hypertension in this model. Resistin was 
identified as a potential mediator of these effects through a novel KATP channel-mediated mechanism. The signif-
icance of resistin in vascular pathophysiology is underpinned by several studies in humans49–51. These findings 
warrant further studies into the molecular mechanism of estrogen’s regulation of resistin expression and how this 
affects KATP channel-mediated vasorelaxation. Utilising a sex-specific approach such as this may open up a unique 
therapeutic avenue for hypertension.
Data Availability
The authors are happy to make materials, data and associated protocols promptly available to readers.
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